Atemezem A, Mbemba E, Vassy R, Slimani H, Saffar L, Gattegno L
Laboratoire de Biologie Cellulaire, JE 2138, Faculté de Médecine Léonard de Vinci, Université Paris XIII, Bobigny 93017, France.
Biochem J. 2001 May 15;356(Pt 1):121-8. doi: 10.1042/0264-6021:3560121.
We have reported previously that human alpha(1)-acid glycoprotein (AGP) inhibits the infection of human monocyte-derived macrophages (MDM) by R5 HIV-1, and that a disulphide-bridged peptide mimicking the clade B HIV-1 gp120 consensus V3 domain (V3Cs) binds specifically to CCR5 (the major co-receptor of R5 HIV strains) on these cells [Seddiki, Rabehi, Benjouad, Saffar, Ferriere, Gluckman and Gattegno (1997) Glycobiology 7, 1229-1236]. The present study demonstrates that AGP binds specifically to MDM at high- and low-affinity binding sites with K(d) values of 16 nM and 4.9 microM respectively. The fact that heat denaturation of AGP only partly inhibited this binding (43%) suggests that protein-protein interactions are involved, as well as AGP glycans which are resistant to heat denaturation. Mannan, but not dextran, is a significant inhibitor (52%) of this binding, and sequential exoglycosidase treatment of AGP, which exposes penultimate mannose residues, has a strong stimulatory effect ( approximately 2.8-fold). Therefore AGP glycans (probably mannose residues) are involved, at least partly, in the binding of AGP to MDM. In addition, AGP inhibits the binding of V3Cs and macrophage inflammatory protein-1beta (MIP-1beta) to MDM. The anti-CCR5 monoclonal antibody 2D7, specific for the second extracellular loop of CCR5, also inhibited AGP binding (67%), whereas anti-CCR5 antibodies specific for the C-terminus of CCR5 region had no effect. Native AGP, like V3Cs (but not heat-denatured AGP), binds to 46 and 33-36 kDa electroblotted AGP-bound MDM membrane ligands, characterized as CCR5 by their interactions with anti-CCR5 antibodies and with MIP-1beta. Therefore both AGP glycans and MDM CCR5 are involved in the binding of AGP to MDM. This suggests that the inhibitory effect of AGP on the infection of human primary macrophages by R5 HIV-1 may be related to specific binding of AGP to a macrophage membrane lectin or lectin-like component and to CCR5.
我们之前曾报道,人α(1)-酸性糖蛋白(AGP)可抑制R5型HIV-1对人单核细胞衍生巨噬细胞(MDM)的感染,且一种模拟B亚型HIV-1 gp120共有V3结构域(V3Cs)的二硫键连接肽可特异性结合这些细胞上的CCR5(R5型HIV毒株的主要共受体)[塞迪基、拉贝希、本乔阿德、萨法尔、费里埃、格鲁克曼和加特尼奥(1997年)《糖生物学》7,1229 - 1236]。本研究表明,AGP分别以K(d)值为16 nM和4.9 μM的高亲和力和低亲和力结合位点特异性结合MDM。AGP热变性仅部分抑制这种结合(43%)这一事实表明,蛋白质 - 蛋白质相互作用以及对热变性有抗性的AGP聚糖都参与其中。甘露聚糖而非葡聚糖是这种结合的显著抑制剂(52%),对AGP进行顺序外切糖苷酶处理以暴露倒数第二个甘露糖残基,具有强烈刺激作用(约2.8倍)。因此,AGP聚糖(可能是甘露糖残基)至少部分参与了AGP与MDM的结合。此外,AGP抑制V3Cs和巨噬细胞炎性蛋白 - 1β(MIP - 1β)与MDM的结合。针对CCR5第二个细胞外环的抗CCR5单克隆抗体2D7也抑制AGP结合(67%),而针对CCR5区域C末端的抗CCR5抗体则无作用。天然AGP与V3Cs一样(但热变性的AGP则不然),可结合46 kDa和33 - 36 kDa经电印迹的与AGP结合的MDM膜配体,通过它们与抗CCR5抗体以及与MIP - 1β的相互作用鉴定为CCR5。因此,AGP聚糖和MDM CCR5都参与了AGP与MDM的结合。这表明AGP对R5型HIV-1感染人原代巨噬细胞的抑制作用可能与AGP与巨噬细胞膜凝集素或凝集素样成分以及CCR5的特异性结合有关。